Abstract
The association of long COVID with health-related quality-of-life (HrQOL) has not been well-characterized. Participants who received blinded placebo in the ACTIV-2/A5401 outpatient COVID-19 treatment trial were included in an analysis of the association of long COVID with HrQOL (both pre-specified exploratory trial endpoints) 9 months after acute COVID-19. Long COVID was defined as presence of self-assessed COVID-19 symptoms and HrQOL was assessed with EQ-5D-5L and SF-36v2 questionnaires. Associations were evaluated by Fisher’s exact tests and Wilcoxon rank-sum tests. Of 546 participants, 13% had long COVID. Long COVID was associated with greater risk of reported problems in the EQ-5D-5L dimensions of mobility, usual activities, pain/discomfort, and anxiety/depression (risk ratios 3.45–6.00, all p < 0.001) and worse self-reported health scores (median 80 vs. 95, p < 0.001). Participants with long COVID also had worse SF-36v2 composite physical and mental component scores (both p < 0.001) and individual SF-36 domain scores (physical functioning, physical role, bodily pain, general health, vitality, social functioning, emotional role, and mental health; all p < 0.001). Associations were similar regardless of baseline (pre-COVID-19) medical history. Long COVID is associated with impaired HrQOL across multiple domains, highlighting the need to develop preventative and therapeutic interventions for this protean condition.
Similar content being viewed by others
Data availability
Data are available under restricted access. Access to the data is governed by ACTG policy. Access can be requested by submitting a data request at https://submit.mis.s-3.net/ and will require the written agreement of ACTG. Requests will be addressed as per ACTG standard operating procedures. Completion of an ACTG Data Use Agreement may be required.
References
Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 21, 133–146 (2023).
Hope, A. A. & Evering, T. H. Postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. Infect. Dis. Clin. North Am. 36, 379–395 (2022).
Groff, D. et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: A systematic review. JAMA Netw. Open 4, e2128568 (2021).
Testa, M. A. & Simonson, D. C. Assessment of quality-of-life outcomes. N Engl. J. Med. 334, 835–840 (1996).
Malik, P. et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)-A systematic review and meta-analysis. J Med. Virol. 94, 253–262 (2022).
Poudel, A. N. et al. Impact of Covid-19 on health-related quality of life of patients: A structured review. PLoS ONE 16, e0259164 (2021).
Malesevic, S. et al. Impaired health-related quality of life in long-COVID syndrome after mild to moderate COVID-19. Sci. Rep. 13, 7717 (2023).
Tabacof, L. et al. Post-acute COVID-19 syndrome negatively impacts physical function, cognitive function, health-related quality of life, and participation. Am. J. Phys. Med. Rehabil. 101, 48–52 (2022).
Currier, J. S. et al. ACTIV-2: a platform trial for the evaluation of novel therapeutics for the treatment of early COVID-19 in outpatients. J. Infect. Dis. 228, S77–S82 (2023).
Chew, K. W. et al. Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19. Nat. Commun. 13, 4931 (2022).
Evering, T. H. et al. Long COVID after Bamlanivimab treatment. J. Infect. Dis. 228, S126–S135 (2023).
Evering, T. H. et al. Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial. EClinicalMedicine 75, 102787 (2024).
EuroQol Research Foundation. EQ-5D-5L User Guide, https://euroqol.org/publications/user-guides. (2019).
Maruish, M. E. E. User’s manual for the SF-36v2 Health Survey 3rd edn. (QualityMetric Incorporated, 2011).
Welcome to MedDRA. Medical Dictionary for Regulatory Activities. https://www.meddra.org.
Evering, T. H. et al. Safety and efficacy of combination SARS-CoV-2 neutralizing monoclonal antibodies Amubarvimab plus Romlusevimab in nonhospitalized patients with COVID-19. Ann. Intern. Med. 176, 658–666 (2023).
Long COVID Basics. (accessed 20 March 2025); https://www.cdc.gov/covid/long-term-effects/index.html.
Meys, R. et al. Generic and Respiratory-specific quality of life in non-hospitalized patients with COVID-19. J. Clin. Med. 9, 3993 (2020).
Lofstrom, E. et al. Health-related quality of life and long-term symptoms among patients with non-severe covid-19 - a prospective cohort study. Infect. Dis. (Lond.) 55, 272–281 (2023).
Nopp, S. et al. Outpatient pulmonary rehabilitation in patients with long COVID improves exercise capacity, functional status, dyspnea, fatigue, and quality of life. Respiration 101, 593–601 (2022).
McIntyre, R. S. et al. Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial. Brain 147, 849–857 (2024).
McGregor, G. et al. Clinical effectiveness of an online supervised group physical and mental health rehabilitation programme for adults with post-covid-19 condition (REGAIN study): multicentre randomised controlled trial. BMJ 384, e076506 (2024).
Acknowledgements
We thank the study participants, site staff, site investigators, and the entire ACTIV-2/A5401 study team; the ACTIV-2 Community Advisory Board; the ACTG, including Lara Hosey, Jhoanna Roa, and Nilam Patel; the University of Washington Virology Specialty Laboratory; the ACTG Laboratory Center; Frontier Science; Harvard Center for Biostatistics in AIDS Research and ACTG Statistical and Data Analysis Center, the National Institute of Allergy and Infectious Diseases/Division of AIDS; the Foundation for the National Institutes of Health and the ACTIV partnership; and the PPD clinical research business of Thermo Fisher Scientific.
Funding
This work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Numbers UM1AI068636, UM1AI068634, UM1AI106701, and P30AI152501. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author information
Authors and Affiliations
Consortia
Contributions
KWC, THE, CM, and MDH conceived and designed the present study. CM, JSC, JJE, ESD, DAW, WF, US, MDH, DMS, THE, and KWC were involved with parent study design and implementation. CM, JR, and MDH conducted statistical analyses. MMG, CM, JR, MDH, and KWC interpreted the data. MMG and KWC drafted the manuscript. All authors reviewed, edited, and approved the manuscript.
Corresponding authors
Ethics declarations
Competing interests
DMS has consulted for the following companies: Model Medicines and Hyundai Biosciences. The remaining authors have no conflicts of interest relevant to this publication.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Gandhi, M.M., Moser, C., Currier, J.S. et al. Association of long COVID with health-related quality-of-life outcomes. Sci Rep (2026). https://doi.org/10.1038/s41598-026-36189-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-36189-8


